
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions is projected to see strong revenue and earnings growth in the current and upcoming year as demand for its biopreservation products, particularly CryoStor, continues to increase. The recent acquisition by Repligen is a strategic move that is seen as the best path forward for BioLife Solutions, given Repligen's scale, commercial reach, and commitment to the cell and gene therapy industry. While the proposed acquisition now largely defines the investment case, BioLife's differentiated position in biopreservation and its exposure to the growing field of cell and gene therapy remain positive factors for future growth and profitability.
Bears say
BioLife Solutions is a life sciences company that provides biopreservation products and services for the cell and gene therapy industry. The company has experienced strong growth in the second quarter of 2026, with revenues increasing 21% year-over-year and adjusted operating income reaching $3.1 million. However, there is uncertainty surrounding the company's future as it is currently in the process of being acquired by Repligen, and the stock is likely to be primarily driven by transaction developments and Repligen's performance until the deal is finalized. As such, a "Hold" rating is appropriate at this time.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares